
Please try another search
Investing.com - Amgen (NASDAQ:AMGN) reported on Thursday first quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Amgen announced earnings per share of $4.17 on revenue of $6.16B. Analysts polled by Investing.com anticipated EPS of $3.74 on revenue of $6B. That with comparison to EPS of $3.56 on revenue of $5.56B in the same period a year before. Amgen had reported EPS of $3.64 on revenue of $6.2B in the previous quarter. Analysts are expecting EPS of $3.88 and revenue of $6.33B in the upcoming quarter.
Amgen shares are down 0% from the beginning of the year , still down 2.46% from its 52 week high of $244.99 set on December 17, 2019. They are under-performing the Nasdaq 100 which is up 2.25% year to date.
Amgen shares gained 0.43% in after-hours trade following the report.
Amgen's report follows an earnings beat by J&J on April 14, who reported EPS of $2.3 on revenue of $20.69B, compared to forecasts EPS of $2.02 on revenue of $19.73B.
Pfizer had beat expectations on Tuesday with first quarter EPS of $0.8 on revenue of $12.03B, compared to forecast for EPS of $0.7 on revenue of $11.34B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.